Coenzyme Q10 and Degenerative Disorders Affecting Longevity: An Overview

Overview

Journal Antioxidants (Basel)

Date 2019 Feb 21

PMID 30781472

Citations 22

Authors

David Mantle

Iain Hargreaves

Affiliations

Soon will be listed here.

Abstract

Longevity is determined by a number of factors, including genetic, environmental and lifestyle factors. A major factor affecting longevity is the development of degenerative disorders such as cardiovascular disease, diabetes, kidney disease and liver disease, particularly where these occur as co-morbidities. In this article, we review the potential role of supplementation with coenzyme Q10 (CoQ10) for the prevention or management of these disorders. Thus, randomised controlled clinical trials have shown supplementation with CoQ10 or CoQ10 plus selenium reduces mortality by approximately 50% in patients with cardiovascular disease, or in the normal elderly population, respectively. Similarly, CoQ10 supplementation improves glycaemic control and vascular dysfunction in type II diabetes, improves renal function in patients with chronic kidney disease, and reduces liver inflammation in patients with non-alcoholic fatty liver disease. The beneficial role of supplemental CoQ10 in the above disorders is considered to result from a combination of its roles in cellular energy generation, as an antioxidant and as an anti-inflammatory agent.

Citing Articles

Diabetes Risks of Statin Therapy-Coenzyme Q10 May Help.

Han X, Liu J, Gu Y, Li Y, Zhang W, Lv N Rev Cardiovasc Med. 2025; 26(2):26437.

PMID: 40026529 PMC: 11868890. DOI: 10.31083/RCM26437.

Physicochemical Properties, Antioxidant Capacity and Bioavailability of Whey Protein Concentrate-Based Coenzyme Q10 Nanoparticles.

Sun Y, Liu J, Pi X, Kemp A, Guo M Antioxidants (Basel). 2025; 13(12.

PMID: 39765863 PMC: 11727553. DOI: 10.3390/antiox13121535.

Exploring the Renoprotective Potential of Bioactive Nutraceuticals in Chronic Kidney Disease Progression: A Narrative Review.

Ghosh A, Muley A, Bhat S, Ainapure A Cureus. 2024; 16(9):e68730.

PMID: 39371767 PMC: 11454842. DOI: 10.7759/cureus.68730.

The relationship between kidney disease and mitochondria: a bibliometric study.

Mao J, Li C, Wu F, Wang Y, Zhu J, Wen C Ren Fail. 2024; 46(1):2302963.

PMID: 38263699 PMC: 10810663. DOI: 10.1080/0886022X.2024.2302963.

Diabetic Nephropathy: Significance of Determining Oxidative Stress and Opportunities for Antioxidant Therapies.

Darenskaya M, Kolesnikov S, Semenova N, Kolesnikova L Int J Mol Sci. 2023; 24(15).

PMID: 37569752 PMC: 10419189. DOI: 10.3390/ijms241512378.

References

Tomasetti M, Alleva R, Solenghi M, Littarru G . Distribution of antioxidants among blood components and lipoproteins: significance of lipids/CoQ10 ratio as a possible marker of increased risk for atherosclerosis. Biofactors. 1999; 9(2-4):231-40. DOI: 10.1002/biof.5520090218. View

Eriksson J, Forsen T, Mortensen S, Rohde M . The effect of coenzyme Q10 administration on metabolic control in patients with type 2 diabetes mellitus. Biofactors. 1999; 9(2-4):315-8. DOI: 10.1002/biof.5520090229. View

Lippa S, Colacicco L, Bondanini F, Calla C, Gozzo M, Ciccariello M . Plasma levels of coenzyme Q(10), vitamin E and lipids in uremic patients on conservative therapy and hemodialysis treatment: some possible biochemical and clinical implications. Clin Chim Acta. 2000; 292(1-2):81-91. DOI: 10.1016/s0009-8981(99)00204-1. View

Mantle D, Preedy V . Free radicals as mediators of alcohol toxicity. Adverse Drug React Toxicol Rev. 2000; 18(4):235-52. View

Hodgson J, Watts G, Playford D, Burke V, Croft K . Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr. 2002; 56(11):1137-42. DOI: 10.1038/sj.ejcn.1601464. View

Yesilova Z, Yaman H, Oktenli C, Ozcan A, Uygun A, Cakir E . Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol. 2005; 100(4):850-5. DOI: 10.1111/j.1572-0241.2005.41500.x. View

Othman A, Shoheib Z, Abdel-Aleem G, Shareef M . Experimental schistosomal hepatitis: protective effect of coenzyme-Q10 against the state of oxidative stress. Exp Parasitol. 2008; 120(2):147-55. DOI: 10.1016/j.exppara.2008.06.009. View

Schmelzer C, Lindner I, Rimbach G, Niklowitz P, Menke T, Doring F . Functions of coenzyme Q10 in inflammation and gene expression. Biofactors. 2008; 32(1-4):179-83. DOI: 10.1002/biof.5520320121. View

Hamilton S, Chew G, Watts G . Coenzyme Q10 improves endothelial dysfunction in statin-treated type 2 diabetic patients. Diabetes Care. 2009; 32(5):810-2. PMC: 2671099. DOI: 10.2337/dc08-1736. View

10.

El-Ghoroury E, Raslan H, Badawy E, El-Saaid G, Agybi M, Siam I . Malondialdehyde and coenzyme Q10 in platelets and serum in type 2 diabetes mellitus: correlation with glycemic control. Blood Coagul Fibrinolysis. 2009; 20(4):248-51. DOI: 10.1097/mbc.0b013e3283254549. View

11.

Choi H, Pokharel Y, Lim S, Han H, Ryu C, Kim S . Inhibition of liver fibrosis by solubilized coenzyme Q10: Role of Nrf2 activation in inhibiting transforming growth factor-beta1 expression. Toxicol Appl Pharmacol. 2009; 240(3):377-84. DOI: 10.1016/j.taap.2009.07.030. View

12.

Fouad A, Jresat I . Hepatoprotective effect of coenzyme Q10 in rats with acetaminophen toxicity. Environ Toxicol Pharmacol. 2012; 33(2):158-67. DOI: 10.1016/j.etap.2011.12.011. View

13.

Alehagen U, Johansson P, Bjornstedt M, Rosen A, Dahlstrom U . Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: a 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. Int J Cardiol. 2012; 167(5):1860-6. DOI: 10.1016/j.ijcard.2012.04.156. View

14.

Macunluoglu B, Kaya Y, Atakan A, Ari E, Kaspar C, Demir H . Serum coenzyme Q10 levels are associated with coronary flow reserve in hemodialysis patients. Hemodial Int. 2012; 17(3):339-45. DOI: 10.1111/hdi.12001. View

15.

Ganesan S, Ito M . Coenzyme Q10 ameliorates the reduction in GLUT4 transporter expression induced by simvastatin in 3T3-L1 adipocytes. Metab Syndr Relat Disord. 2013; 11(4):251-5. DOI: 10.1089/met.2012.0177. View

16.

Kolahdouz Mohammadi R, Hosseinzadeh-Attar M, Eshraghian M, Nakhjavani M, Khorami E, Esteghamati A . The effect of coenzyme Q10 supplementation on metabolic status of type 2 diabetic patients. Minerva Gastroenterol Dietol. 2013; 59(2):231-6. View

17.

Johansson P, Dahlstrom O, Dahlstrom U, Alehagen U . Effect of selenium and Q10 on the cardiac biomarker NT-proBNP. Scand Cardiovasc J. 2013; 47(5):281-8. DOI: 10.3109/14017431.2013.820838. View

18.

Madmani M, Yusuf Solaiman A, Agha K, Madmani Y, Shahrour Y, Essali A . Coenzyme Q10 for heart failure. Cochrane Database Syst Rev. 2013; (6):CD008684. DOI: 10.1002/14651858.CD008684.pub2. View

19.

Ates O, Bilen H, Keles S, Alp H, Keles M, Yildirim K . Plasma coenzyme Q10 levels in type 2 diabetic patients with retinopathy. Int J Ophthalmol. 2013; 6(5):675-9. PMC: 3808920. DOI: 10.3980/j.issn.2222-3959.2013.05.24. View

20.

Hargreaves I . Coenzyme Q10 as a therapy for mitochondrial disease. Int J Biochem Cell Biol. 2014; 49:105-11. DOI: 10.1016/j.biocel.2014.01.020. View